Fresenius Medical Care said it expects revenue in 2020 to reach $28 billion. The dialysis provider announced its ambitious revenue guidance at a Capital Markets Day on April 3 in New York. This guidance represents a cumulative average growth rate of around 10% per annum and a near doubling of revenue compared to 2013, when it brought in $14.6 billion.
The event, hosted by FMC, was aimed at giving analysts and investors further insight into the dialysis provider's vision for 2020 and the growth and efficiency strategies the company is pursuing. The event included presentations by chief executive officer Rice Powell and other members of the senior management team on global strategy, regional business strategies, R&D, manufacturing, medical therapy and financials.
FMC executives said they plan to increase the company's dialysis products and services business around the world, and save $300 million per year in efficiency gains by 2017, according to a news release. They also said they see significant potential in care coordination, which is an extension of the company’s renal care for its patients and currently includes vascular care, laboratory, and pharmacy businesses. FMC plans to build this business segment and expects revenue from care coordination to grow from 3% of total revenue in 2013 to about 18% in 2020.